EACS 2025

EACS 2025
October 15-18, 2025
Paris, France

European AIDS Clinical Society.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (15)

    ART persistence among treatment-experienced people with HIV and mental health disorders in the US

    • Author(s): Mordi, U
    • biktarvy
    • HIV / AIDS
    • Poster

    Commonly prescribed concomitant medications and clinical safety findings with Lenacapavir for PrEP in PURPOSE 2

    • Author(s): Avihingsanon, A
    • yeztugo
    • HIV / AIDS
    • Poster

    Treatment outcomes in people with a late HIV diagnosis: a pooled analysis of participants with advanced HIV disease at diagnosis randomized to receive B/F/TAF

    • Author(s): Rockstroh, JK
    • biktarvy
    • HIV / AIDS
    • Poster

    Pharmacokinetics and safety data after switching from injectable CAB+ RPV to oral B/F/TAF

    • Author(s): Arora, P
    • biktarvy
    • HIV / AIDS
    • Poster

    Oral weekly ISL/LEN in VS PWH: 96 week outcomes from a Phase 2 study

    • Author(s): Colson, A
    • lenacapavir plus islatravir
    • HIV / AIDS
    • Oral

    Annual persistence to twice-yearly Lenacapavir vs daily oral F/TDF for PrEP in the PURPOSE 2 trial

    • Author(s): Ogbuagu, O
    • yeztugo
    • HIV / AIDS
    • Oral

    Patient-reported outcomes from PWH receiving once-weekly oral Islatravir in combination with Lenacapavir: Phase 2 Week 48 results

    • Author(s): Eron, J
    • lenacapavir plus islatravir
    • HIV / AIDS
    • Poster

    Five-year extended follow-up of the observational BICSTAR cohort: final analysis in PWH receiving B/F/TAF in routine clinical practice

    • Author(s): de Wet, J
    • biktarvy
    • HIV / AIDS
    • Poster

    High in-vitro resistance barrier for the Bictegravir/Lenacapavir combination

    • Author(s): D’Antoni, ML
    • lenacapavir in combination with bictegravir
    • HIV / AIDS
    • Poster

    Recruitment of disproportionately affected populations in the PURPOSE 5 study evaluating Lenacapavir for PrEP in France and the UK

    • Author(s): Molina, JM
    • yeztugo
    • HIV / AIDS
    • Oral

    Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a BIC/LEN STR with complex ART regimens

    • Author(s): Hedgcock, M
    • lenacapavir in combination with bictegravir
    • HIV / AIDS
    • Poster

    The potential impact of twice-yearly injectable Lenacapavir among cisgender gay, bisexual, and other MSM (GBMSM) and other priority HIV Prevention populations (transgender people and highly exposed heterosexual people) in France

    • Author(s): Zeggagh, J
    • yeztugo
    • HIV / AIDS
    • Poster

    DDI liability of BIC and LEN compared with commonly used components of complex ART regimens in ARTISTRY-1

    • Author(s): Arora, P
    • lenacapavir in combination with bictegravir
    • HIV / AIDS
    • Poster

    Efficacy and safety of a twice-yearly regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 results

    • Author(s): Ogbuagu, O
    • lenacapavir in combination with bnabs
    • HIV / AIDS
    • Oral

    Safety and analytical treatment interruption outcomes in a Clinical Trial of 2 broadly neutralizing antibodies plus Vesatolimod in early-treated South African women with Clade C HIV-1

    • Author(s): Lim, D
    • vestalimod (gs-9620)
    • HIV / AIDS
    • Oral